Article
Phenotypic amikacin resistance may not indicate poor response to amikacin in Mycobacterium avium complex pulmonary disease.
Antimicrobial agents and chemotherapy - 5 Jun 2024
Minuk L M, Brode S K, Mehrabi M, Sharma M K, Stobart M, Soualhine H, Marras T K
Abstract excerpt
When using amikacin to treat Mycobacterium avium complex pulmonary disease (MAC-PD), a minimum inhibitory concentration resistance breakpoint of ≥64 mcg/mL is recommended. We explored whether amikacin resistance characterized by phenotypic drug susceptibility testing was associated with clinical outcomes or mutational resistance in a retrospective cohort of patients with MAC-PD. Despite little aminoglycoside...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
